If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

You might think a biotech company that created a new vaccine, using novel tech like mRNA-based therapeutics, in record time to help the world fight a historic pandemic like COVID-19 would still be ...

New research from the University of Pittsburgh could help scientists develop the next generation of mRNA vaccines to be more effective and less expensive to produce. A study published this week in NPJ ...

In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the original COVID-19 mRNA vaccine with an immune system enhancer, known as an ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and ...

As the buzz builds around messenger RNA (mRNA) technology’s use for two leading COVID-19 candidates, manufacturers and regulatory professionals are facing facts: This is not simple technology. Complex ...

IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...

An mRNA therapy efficaciously corrected—in a mouse model—altered glutathione metabolism, offering a prospective avenue for treating argininosuccinic aciduria (ASA), an inherited metabolic disorder.

A pair of pessimistic third-quarter earnings calls from pharmaceutical giants Pfizer and Moderna, tracking decreased coronavirus vaccine demand and declining revenue projections, suggests biotech ...